Biocon Biologics to buy biosimilars business of Viatris for up to $3.3bn
Biocon Biologics Limited (BBL), a subsidiary of Indian biopharma company Biocon, has agreed to acquire the biosimilars business of Viatris, a US-based pharma company, in ... Read More
Biocon Biologics, Viatris launch interchangeable biosimilars in US
Biocon Ltd. said that its subsidiary — Biocon Biologics and Viatris have launched interchangeable biosimilars SEMGLEE (insulin glargine-yfgn) injection, a branded product, and Insulin Glargine ... Read More
Biocon to sell 15% stake in Biocon Biologics to Serum Institute of India
Biocon has agreed to divest a stake of around 15% in its subsidiary — Biocon Biologics Limited (BBL) to Serum Institute Life Sciences Private Limited ... Read More
Biocon gets license for Adagio Therapeutics’ ADG20 for Covid-19 treatment
Biocon Limited said that its subsidiary Biocon Biologics has been given an exclusive license from Adagio Therapeutics, a US-based biotech company, for manufacturing and commercializing ... Read More
Biocon, Libbs Farmaceutica team up for launching generic drugs in Brazil
Biocon Ltd, an Indian biopharma company, has entered into a partnership with Brazilian pharma company Libbs Farmaceutica for launching generic drugs in Brazil. The company ... Read More
Mylan, Biocon get FDA approval for Semglee in type 1 and 2 diabetes
Mylan and Biocon have secured approval from the US Food and Drug Administration (FDA) for Semglee (insulin glargine injection) in vial and pre-filled pen presentations ... Read More